United Capital Financial Advisors LLC Purchases Shares of 4,155 Alnylam Pharmaceuticals, Inc. $ALNY

United Capital Financial Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,155 shares of the biopharmaceutical company’s stock, valued at approximately $1,251,000.

A number of other large investors have also bought and sold shares of ALNY. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $243,000. Geneos Wealth Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 175 shares during the last quarter. Flow Traders U.S. LLC bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $241,000. Daiwa Securities Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after acquiring an additional 35 shares during the period. Finally, NewEdge Advisors LLC increased its holdings in Alnylam Pharmaceuticals by 70,300.0% during the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 703 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Up 0.2%

Shares of ALNY stock opened at $237.10 on Friday. The company has a market capitalization of $31.73 billion, a PE ratio of 44.07 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55. The business’s fifty day moving average is $262.62 and its 200 day moving average is $293.73. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company’s revenue was up 66.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.51) EPS. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ALNY. Bank of America lowered their price objective on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Stifel Nicolaus reduced their target price on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Truist Financial lowered their price target on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. JPMorgan Chase & Co. cut their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, Chardan Capital reiterated a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $386.14.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.